KORU Medical Systems, Inc. (NASDAQ:KRMD) Given Average Rating of “Moderate Buy” by Analysts

Shares of KORU Medical Systems, Inc. (NASDAQ:KRMD) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $6.50.

KRMD has been the topic of a number of research analyst reports. Lake Street Capital boosted their target price on shares of KORU Medical Systems from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, December 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of KORU Medical Systems in a research note on Thursday, January 22nd. Wall Street Zen upgraded shares of KORU Medical Systems from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Canaccord Genuity Group reiterated a “buy” rating and issued a $6.00 target price on shares of KORU Medical Systems in a research note on Friday, March 13th. Finally, B. Riley Financial boosted their target price on shares of KORU Medical Systems from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, March 13th.

KORU Medical Systems Stock Down 1.6%

KRMD opened at $4.26 on Tuesday. The stock has a market cap of $198.56 million, a price-to-earnings ratio of -71.00 and a beta of 0.55. KORU Medical Systems has a twelve month low of $2.18 and a twelve month high of $6.61. The company’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $4.85.

KORU Medical Systems (NASDAQ:KRMD) last released its earnings results on Thursday, March 12th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The firm had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $10.90 million. KORU Medical Systems had a negative net margin of 6.41% and a negative return on equity of 15.90%. As a group, sell-side analysts anticipate that KORU Medical Systems will post -0.03 earnings per share for the current year.

Institutional Trading of KORU Medical Systems

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its stake in shares of KORU Medical Systems by 52.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,148 shares of the company’s stock valued at $39,000 after buying an additional 3,478 shares in the last quarter. Lazard Asset Management LLC purchased a new stake in shares of KORU Medical Systems during the 2nd quarter valued at approximately $59,000. Occudo Quantitative Strategies LP purchased a new stake in shares of KORU Medical Systems during the 4th quarter valued at approximately $127,000. Invesco Ltd. purchased a new stake in shares of KORU Medical Systems during the 2nd quarter valued at approximately $80,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of KORU Medical Systems during the 2nd quarter valued at approximately $83,000. 58.60% of the stock is currently owned by hedge funds and other institutional investors.

About KORU Medical Systems

KORU Medical Systems, Inc develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products.